Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)
Sponsor: Chinese University of Hong Kong
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.
Official title: A Phase II Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) for Prostate Cancer (Fez-Cap)
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2026-07-01
Completion Date
2028-03-31
Last Updated
2026-05-05
Healthy Volunteers
No
Conditions
Interventions
Fezolinetant
Fezolinetant 45 mg orally once daily for 12 weeks.
Placebo
Placebo orally once daily for 12 weeks.
Locations (1)
Prince of Wales Hospital
Shatin, Hong Kong